ALCIDION GROUP LIMITED (ALC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ALC

ALC - ALCIDION GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.35
Index:

Alcidion Group provides clinical information technology to support clinicians in decision making, ensuring quality of care for patients. The company operates in Australia and the UK. It listed on the ASX in 2011.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.14

15 Jan
2026

0.000

OPEN

$0.14

0.000

HIGH

$0.14

22,142,994

LOW

$0.13

TARGET
$0.17

+0.03 change from previous day

 21.4% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . BMT . DOC . EBO . HLS . IDX . M7T . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
ALC: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 0.1 0.4 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A 100.0% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 33.3 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx0.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx40.8 M
Book Value Per Share xxxxxxxxxxxxxxx6.5
Net Operating Cash Flow xxxxxxxxxxxxxxx5.8 M
Net Profit Margin xxxxxxxxxxxxxxx4.06 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx1.89 %
Return on Invested Capital xxxxxxxxxxxxxxx1.87 %
Return on Assets xxxxxxxxxxxxxxx1.44 %
Return on Equity xxxxxxxxxxxxxxx1.89 %
Return on Total Capital xxxxxxxxxxxxxxx-0.63 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx5.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx68 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx18 M
Price To Book Value xxxxxxxxxxxxxxx1.53

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx0.31 %
Cost of Goods Sold xxxxxxxxxxxxxxx36 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

16/01/2026

1

Buy

$0.17

21.43%

Alcidion Group's 2Q26 trading update revealed FY26 contracted revenue is around $43.1m, a rise of $6.8m on the previous quarter and above FY25 revenue by 6%, Bell Potter explains.

FY26 earnings (EBITDA) guidance was upgraded with operating cashflow expectations moving to "positive" from "at least in line with FY25, with potential upside".

The analyst believes the new earnings (EBITDA) guidance over $4.8m and operating cashflow over $5.8m are very achievable. Further, the guidance on contracted revenue came in above previous expectations for FY26 contracted revenue.

Bell Potter has raised its FY26, FY27 and FY28 revenue forecasts by around $6m per annum or 11%-13% on the back of the update.

Target price 17c. No change to Buy rating.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.39 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.48 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

08/01/2026

1

Buy

$0.13

-7.14%

Canaccord Genuity highlights Alcidion Group’s appointment as preferred supplier for an electronic patient records system at University Hospitals Sussex, adding $35m in contracted revenue over at least seven years.

The broker forecasts FY26 revenue will rise to around $50m, assuming roughly $8m is recognised from the contract, exceeding prior forecasts and pushing earnings (EBITDA) beyond breakeven.

The award reinforces confidence in earnings-positive guidance, according to the analysts, and validates the land-and-expand strategy. Further module additions or extensions are considered possible before March 2026.

Canaccord retains a Buy rating and target of 13c.
Access Extra Coverage Research History >

ALC STOCK CHART

FNArena News on ALC

1
Australian Broker Call *Extra* Edition – Jan 14, 2026

Jan 14 2026 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Dec 10, 2025

Dec 10 2025 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Nov 20, 2025

Nov 20 2025 - Daily Market Reports
4
Weekly Ratings, Targets, Forecast Changes – 29-08-25

Sep 01 2025 - Weekly Reports
5
FNArena Corporate Results Monitor – 29-08-2025

Aug 29 2025 - Australia

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps